NEVANIMIBE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C27H39N3O
Molecular Weight	421.6181
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(C)C1=CC=CC(C(C)C)=C1NC(=O)NCC2(CCCC2)C3=CC=C(C=C3)N(C)C

InChI

InChIKey=PKKNCEXEVUFFFI-UHFFFAOYSA-N

InChI=1S/C27H39N3O/c1-19(2)23-10-9-11-24(20(3)4)25(23)29-26(31)28-18-27(16-7-8-17-27)21-12-14-22(15-13-21)30(5)6/h9-15,19-20H,7-8,16-18H2,1-6H3,(H2,28,29,31)

HIDE SMILES / InChI

Molecular Formula	C27H39N3O
Molecular Weight	421.6181
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7899779 | https://clinicaltrials.gov/ct2/show/NCT03669549 | https://www.millendo.com/our-programs/nevanimibe.php

Nevanimibe (also known as PD-132301 and ATR101) is an acetyl-CoA C-acyltransferase (ACAT1) inhibitor. Millendo Therapeutics is currently advancing the development of nevanimibe for the treatment of two orphan adrenal diseases: classic congenital adrenal hyperplasia (CAH) and endogenous Cushing's syndrome (CS). Both of these diseases are associated with an overactive adrenal cortex causing excess steroid production. Millendo believes that nevanimibe represents an adrenal-specific approach that will address these diseases through the reduction of adrenal steroid production. Millendo is currently conducting Phase 2 clinical trial to assess the safety and efficacy of nevanimibe in subjects with endogenous Cushing’s syndrome and for the treatment of adult CAH.

Originator

Approval Year

PubMed

Title	Date	PubMed
Morphogenesis of a zone-specific adrenocortical cytotoxicity in guinea pigs administered PD 132301-2, an inhibitor of acyl-CoA:cholesterol acyltransferase.	1993	8397438
Toxicologic effects of a novel acyl-CoA:cholesterol acyltransferase inhibitor in cynomolgus monkeys.	1994 Sep-Oct	7899779
Biochemical alterations in guinea pig adrenal cortex following administration of PD 132301-2, an inhibitor of acyl-CoA:cholesterol acyltransferase.	1995 Feb 17	9001442

Sample Use Guides

In Vivo Use Guide

During the 12-week treatment period, all subjects will begin dosing with nevanimibe HCl (PD-132301) 1000 mg BID and be dose titrated to 1500 mg BID and then 2000 mg BID based upon the 17-OHP response that will be assessed every 4 weeks.

Route of Administration: Oral

Substance Class	Chemical Created by `admin` on `Sat Dec 16 02:14:00 GMT 2023` Edited by `admin` on `Sat Dec 16 02:14:00 GMT 2023`
Record UNII	VK9OS8R205
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

NEVANIMIBE

Official Name

English

PD 132301

Code

English

ATR-101 FREE BASE

Code

English

PD-132301

Code

English

UREA, N-(2,6-BIS(1-METHYLETHYL)PHENYL)-N'-((1-(4-(DIMETHYLAMINO)PHENYL)CYCLOPENTYL)METHYL)-

Systematic Name

English

NEVANIMIBE [USAN]

Common Name

English

N-(2,6-BIS(PROPAN-2-YL)PHENYL)-N'-((1-(4-(DIMETHYLAMINO)PHENYL) CYCLOPENTYL)METHYL)UREA

Systematic Name

English

nevanimibe [INN]

Common Name

English

Classification Tree Code System Code

FDA ORPHAN DRUG

497315